Erschienen in:
01.06.2009 | Original Paper
Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer
verfasst von:
Jaime Coronel, Lucely Cetina, Myrna Candelaria, Aurora González-Fierro, Daimy Arias, David Cantu, Alfonso Dueñas-González
Erschienen in:
Medical Oncology
|
Ausgabe 2/2009
Einloggen, um Zugang zu erhalten
Abstract
Topotecan is active in advanced or metastatic cervical cancer even in patients who have received prior cisplatin-based chemotherapy, although hematologic toxicity has limited its use. Studies in cervical cancer have utilized topotecan administered on days 1–5 of each 21- or 28-day cycle. Alternative schedules, such as weekly schemes, have proven to ameliorate hematological toxicity. The objective of this study was to analyze the results of weekly topotecan as second- or third-line therapy in advanced or metastatic cervical cancer. Eligible patients had histologically confirmed cervical carcinoma, measurable disease, and at least one prior chemotherapy regimen. Topotecan was administered at a dose of 3 mg/m2 (maximum, 5 mg per dose) diluted in 250 ml of normal saline in a 30-min infusion weekly for every 28 days. We assessed response and toxicity. Twenty-two patients entered this study. Eighteen patients were evaluable for toxicity and response. Patients received a mean 3.5 courses (range, 1–6 courses). No complete or partial responses were observed; five (27.7%) patients exhibited disease stabilization as maximum response (two in irradiated sites, and three in lung/mediastinum). Median progression-free interval was 3.5 months (95% confidence interval [CI]: 3.75–4 months) and median overall survival was 7 months (95% CI: 6–8.7 months). Weekly topotecan administration achieved disease stabilization in 27.7% of heavily pre-treated patients. The achievement could be of worth in this setting in which disease prolongation is desirable.